Peptide mimotopes of claudin 18.2 and uses thereof

A method for treating a patient affected from a cancer characterized by cancer cells expressing CLDN18.2 comprising a step of administering to the patient a cell comprising a chimeric antigen receptor (CAR), the CAR comprising a single-chain variable fragment (scFV) fused to a CD3-zeta transmembrane and endodomain,

• wherein said scFV comprises a heavy chain variable region (VH) and a light chain variable region (VL), each comprising a set of three complementarity-determining regions (CDR1, CDR2, and CDR3),
• wherein the VH CDR1, CDR2, and CDR3 have the amino acid sequences of positions 45-52, positions 70-77, and positions 116-126 of SEQ ID NO:
• 12, respectively, and
• wherein the VL CDR1, CDR2, and CDR3 have the amino acid sequences of positions 47-58, positions 76-78, and positions 115-123 of SEQ ID NO:
• 13, respectively.

A method for treating a patient affected from a cancer characterized by cancer cells expressing CLDN18.2 comprising a step of administering to the patient an immune effector cell comprising a chimeric antigen receptor (CAR), the CAR comprising a single-chain variable fragment (scFV) fused to a CD3-zeta transmembrane and endodomain,

• wherein said scFV comprises a heavy chain variable region (VH) and a light chain variable region (VL), each comprising a set of three complementarity-determining regions (CDR1, CDR2, and CDR3),
• wherein the VH CDR1, CDR2, and CDR3 have the amino acid sequences of positions 45-52, positions 70-77, and positions 116-126 of SEQ ID NO:
• 12, respectively, and
• wherein the VL CDR1, CDR2, and CDR3 have the amino acid sequences of positions 47-58, positions 76-78, and positions 115-123 of SEQ ID NO:
• 13, respectively;
• and
• wherein the CAR is expressed on the cell surface of said immune effector cell.